What's the Difference Between Liraglutide, Semaglutide, and Tirzepatide?
Quick Answer
All three are injectable incretin therapies used for weight management and type 2 diabetes, but they are not interchangeable. Liraglutide (Victoza, Saxenda) is a once-daily GLP-1 receptor agonist and the oldest of the three, approved by the FDA in 2010. Semaglutide (Ozempic, Rybelsus, Wegovy) is a once-weekly GLP-1 receptor agonist engineered for a much longer half-life. Tirzepatide (Mounjaro, Zepbound) is a once-weekly dual GIP/GLP-1 receptor agonist, the newest and most potent of the three. In genuine head-to-head randomized trials, not just separate comparisons to placebo, semaglutide produced significantly more weight loss and better glycemic control than liraglutide, and tirzepatide produced significantly more weight loss than semaglutide. All three carry the same FDA boxed warning for thyroid C-cell tumors seen in rodent studies.
The Head-to-Head Trials, Not Just Separate Comparisons to Placebo
The most reliable way to compare these drugs is a trial that randomizes patients directly against each other, and that evidence exists for two of the three pairings. In STEP 8, 338 adults with overweight or obesity were randomized to semaglutide 2.4 mg weekly, liraglutide 3.0 mg daily, or placebo, for 68 weeks. Semaglutide produced a mean body weight change of -15.8%, versus -6.4% with liraglutide and -1.9% with placebo, a between-group difference of 9.4 percentage points favoring semaglutide (95% CI 6.8-12.0, p<0.001). More than three times as many semaglutide patients reached at least 10% weight loss (70.9% versus 25.6%), and fewer discontinued treatment overall (13.5% versus 27.6%), though both drugs produced GI side effects at a similar overall rate (84.1% versus 82.7%). In SUSTAIN 10, 577 adults with type 2 diabetes were randomized to semaglutide 1.0 mg weekly or liraglutide 1.2 mg daily for 30 weeks. Semaglutide produced a larger HbA1c reduction (1.7 percentage points versus 1.0, a treatment difference of 0.69 points, p<0.0001) and more weight loss (5.8 kg versus 1.9 kg), and four times as many patients reached an HbA1c below 7.0% (80% versus 46%). For tirzepatide against semaglutide, SURMOUNT-5 randomized 751 adults with obesity to tirzepatide or semaglutide directly for 72 weeks: tirzepatide produced significantly greater weight loss, -20.2% versus -13.7% (p<0.001), and greater waist circumference reduction. I did not find a published head-to-head trial of tirzepatide against liraglutide directly; the comparison between those two rests on their separate placebo-controlled trials (SURMOUNT-1 and SCALE) rather than a direct randomization, which is weaker evidence than the two head-to-head trials above and should be read that way.
The mechanism, safety profile, and full independent trial evidence behind each of these drugs on its own, including semaglutide's SELECT cardiovascular trial, tirzepatide's SURPASS and SURMOUNT program, and liraglutide's own LEADER cardiovascular outcomes trial and gallbladder safety signal, are covered in the three full guides: Liraglutide, Semaglutide, and Tirzepatide.
Why Anyone Would Still Choose Liraglutide
Liraglutide is not the more effective choice for either weight loss or glycemic control based on the head-to-head data above. It remains a reasonable option in specific situations: its shorter half-life, about 13 hours versus roughly a week for the other two, means its effects clear the body faster if it's not tolerated or needs to stop before a procedure, and once-daily dosing allows finer, more gradual dose adjustments than the larger jumps built into weekly titration schedules.
If you're already a patient at one of my clinics, bring this up with your care team directly before starting or switching between any of these therapies. If you'd like an in-clinic consultation, here are all of the practices I see patients in. Prefer to start with a question first? Reach out directly by email or Instagram.
View My Clinic LocationsOr email drwilcox@precisionhormoneconsulting.com · DM @wellnessdoc_4everyoung on Instagram
— Dr. Darrell Wilcox · @wellnessdoc_4everyoung on Instagram
References
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619 · PMID: 35015037
- Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100-109. doi:10.1016/j.diabet.2019.101117
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394 · PMID: 40353578
- U.S. Food and Drug Administration. SAXENDA (liraglutide) injection, prescribing information (boxed warning: thyroid C-cell tumors). accessdata.fda.gov.
This content is for educational purposes only and does not constitute medical advice. Liraglutide, semaglutide, and tirzepatide are FDA-approved prescription medications; specific formulations and indications vary by brand. Individual clinical decisions require physician evaluation and are made on a case-by-case basis. Dr. Wilcox is licensed to practice in multiple states. See About for current licensure.